Plain-English translation of NCT06275958 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
The DOSAGE study is testing whether starting with lower doses of chemotherapy works just as well as full doses for older adults (age 70 and up) with advanced colorectal cancer. Researchers will give you a brief health screening questionnaire to assess your individual risk of side effects, then assign you to either a lower or standard dose of chemotherapy. The goal is to help you live longer while protecting you from severe side effects and keeping your quality of life as good as possible.
Older adults often experience more serious side effects from chemotherapy than younger patients, which can mean more hospital visits, worse quality of life, and higher healthcare costs. Currently, there are no clear guidelines for treating older patients, so doctors aren't sure whether lower doses from the start might be just as effective while causing fewer problems.
You likely qualify if…
You likely don't qualify if…
First, you'll complete a short questionnaire to assess your overall health and risk of treatment side effects. Based on your results, you'll be randomly assigned to receive either standard-dose or lower-dose chemotherapy. You'll visit the hospital regularly for treatment infusions and check-ups, where doctors will monitor how well the treatment is working and watch for any side effects. The study will track how long you survive without your cancer getting worse, how many serious side effects you experience, and how your quality of life and physical strength change over time.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Netherlands